FBLG Logo

FibroBiologics, Inc. Common Stock (FBLG) Stock Forecast & Price Prediction

Live FBLG Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$1.86

+0.26 (16.25%)

12 Month Price Forecast For FBLG

$1.86
Current Price
$58.25M
Market Cap
3 Ratings
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to FBLG Price Forecasts

+760.2%
To High Target of $16.00
+545.2%
To Median Target of $12.00
+491.4%
To Low Target of $11.00

FBLG Price Momentum

+15.5%
1 Week Change
-9.7%
1 Month Change
-76.2%
1 Year Change
-7.0%
Year-to-Date Change
-89.5%
From 52W High of $17.75
+72.5%
From 52W Low of $1.08

๐Ÿค” Considering FibroBiologics (FBLG)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 11:12 AM UTC

FBLG Analyst Ratings & Price Targets

Based on our analysis of 4 Wall Street analysts, FBLG has a consensus that is bullish. The median price target is $12.00, with forecasts ranging from $11.00 to $16.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With FBLG currently trading at $1.86, the median price forecast suggests a 545.2% upside. The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 760.2% upside, while at provides the most conservative target, suggesting a 491.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

FBLG Analyst Consensus

3
Buy
0
Hold
0
Sell

FBLG Price Target Range

Low
$11.00
Average
$12.00
High
$16.00
Current: $1.86

Latest FBLG Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for FBLG.

Date Firm Analyst Rating Change Price Target
Dec 27, 2024 D. Boral Capital Jason Kolbert Buy Maintains $16.00
Dec 12, 2024 Rodman & Renshaw Elemer Piros Buy Initiates $12.00
Nov 20, 2024 D. Boral Capital Jason Kolbert Buy Maintains $16.00
Nov 13, 2024 D. Boral Capital Jason Kolbert Buy Maintains $16.00
Nov 13, 2024 HC Wainwright & Co. Matthew Caufield Buy Reiterates $12.00
Oct 30, 2024 HC Wainwright & Co. Matthew Caufield Buy Initiates $12.00
Oct 18, 2024 EF Hutton Jason Kolbert Buy Maintains $16.00
Sep 24, 2024 Maxim Group Michael Okunewitch Buy Initiates $12.00
Sep 13, 2024 EF Hutton Jason Kolbert Buy Maintains $16.00
Sep 4, 2024 EF Hutton Jason Kolbert Buy Initiates $16.00

Stocks Similar to FibroBiologics, Inc. Common Stock

The following stocks are similar to FibroBiologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

FibroBiologics, Inc. Common Stock (FBLG) Financial Data

FibroBiologics, Inc. Common Stock has a market capitalization of $58.25M with a P/E ratio of -3.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -267.9%.

Valuation Metrics

Market Cap $58.25M
Enterprise Value $49.19M
P/E Ratio -3.2x
PEG Ratio -4.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +12.2%
Current Ratio 1.2x
Debt/Equity 57.1x
ROE -267.9%
ROA -65.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

FibroBiologics, Inc. Common Stock logo

FibroBiologics, Inc. Common Stock (FBLG) Company Overview

About FibroBiologics, Inc. Common Stock

What They Do

Develops cell therapy for chronic diseases.

Business Model

FibroBiologics, Inc. generates revenue through the development and commercialization of innovative cell therapy treatments derived from fibroblast cells. The company is focusing on a diverse pipeline targeting various chronic conditions, which positions it to potentially monetize its patented technologies through licensing agreements or partnerships with larger healthcare firms.

Additional Information

With over 150 patents issued or pending, FibroBiologics is strongly positioned in the regenerative medicine field. Incorporated in 2021 and headquartered in Houston, Texas, the company focuses on multiple therapeutic areas, including orthopedics and cancer, indicating a broad market potential and opportunities for growth.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

10

CEO

Mr. Peter O'Heeron

Country

United States

IPO Year

N/A

FibroBiologics, Inc. Common Stock (FBLG) Latest News & Analysis

FBLG stock latest news image
Quick Summary

FibroBiologics, Inc. will host an analyst day on February 12, 2025, in New York, focusing on its fibroblast-based therapeutics for chronic diseases. Key executives will present.

Why It Matters

FibroBiologics' analyst day could signal strategic advancements in its R&D, potentially impacting stock performance and investor sentiment around its innovative therapies for chronic diseases.

Source: GlobeNewsWire
Market Sentiment: Neutral
FBLG stock latest news image
Quick Summary

FibroBiologics (Nasdaq: FBLG) has signed a Standby Equity Purchase Agreement with Yorkville Advisors, enabling the sale of up to $25 million in common stock over two years.

Why It Matters

The SEPA enables FibroBiologics to raise capital, enhancing liquidity for research and development, which could accelerate growth and impact stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
FBLG stock latest news image
Quick Summary

FibroBiologics (Nasdaq: FBLG) has closed a $5 million tranche of a Standby Equity Purchase Agreement with Yorkville, allowing it to sell up to $25 million in stock over two years.

Why It Matters

FibroBiologics secured $5 million in funding, enhancing its financial stability and growth potential in chronic disease therapeutics, which may attract investor interest and influence stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
FBLG stock latest news image
Quick Summary

FibroBiologics (Nasdaq: FBLG) has signed a Standby Equity Purchase Agreement with Yorkville, enabling it to sell up to $25 million in common stock over two years.

Why It Matters

FibroBiologics' SEPA with Yorkville provides potential access to $25 million, enhancing liquidity for R&D. Investor sentiment may shift based on funding security and growth prospects.

Source: GlobeNewsWire
Market Sentiment: Neutral
FBLG stock latest news image
Quick Summary

FibroBiologics, Inc. (Nasdaq: FBLG) has filed a patent for a cell-based therapy to treat splenomegaly, expanding its portfolio focused on chronic disease therapeutics.

Why It Matters

FibroBiologics' new patent application for treating splenomegaly signals potential advancements in their therapeutic portfolio, which could enhance market value and investor interest.

Source: GlobeNewsWire
Market Sentiment: Neutral
FBLG stock latest news image
Quick Summary

A Phase 1/2 clinical trial for the fibroblast-based product candidate CYWC628, aimed at treating diabetic foot ulcers, is set to begin in Australia in Q2 2025.

Why It Matters

The advancement of CYWC628's clinical trial for diabetic foot ulcers signals potential market entry and revenue growth, impacting the company's valuation and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About FBLG Stock

What is FibroBiologics, Inc. Common Stock's (FBLG) stock forecast for 2025?

Based on our analysis of 4 Wall Street analysts, FibroBiologics, Inc. Common Stock (FBLG) has a median price target of $12.00. The highest price target is $16.00 and the lowest is $11.00.

Is FBLG stock a good investment in 2025?

According to current analyst ratings, FBLG has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.86. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for FBLG stock?

Wall Street analysts predict FBLG stock could reach $12.00 in the next 12 months. This represents a 545.2% increase from the current price of $1.86. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is FibroBiologics, Inc. Common Stock's business model?

FibroBiologics, Inc. generates revenue through the development and commercialization of innovative cell therapy treatments derived from fibroblast cells. The company is focusing on a diverse pipeline targeting various chronic conditions, which positions it to potentially monetize its patented technologies through licensing agreements or partnerships with larger healthcare firms.

What is the highest forecasted price for FBLG FibroBiologics, Inc. Common Stock?

The highest price target for FBLG is $16.00 from Jason Kolbert at D. Boral Capital, which represents a 760.2% increase from the current price of $1.86.

What is the lowest forecasted price for FBLG FibroBiologics, Inc. Common Stock?

The lowest price target for FBLG is $11.00 from at , which represents a 491.4% increase from the current price of $1.86.

What is the overall FBLG consensus from analysts for FibroBiologics, Inc. Common Stock?

The overall analyst consensus for FBLG is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.

How accurate are FBLG stock price projections?

Stock price projections, including those for FibroBiologics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.